Imagine discovering you have prostate cancer without ever experiencing a single symptom. That’s exactly what happened to Junior Hemans during a routine health check in 2014, at just 51 years old. But here’s where it gets controversial: despite knowing his heightened risk as a Black man, Hemans had to specifically request a prostate-specific antigen (PSA) test—a test not routinely offered by the NHS. This glaring gap in screening protocols has sparked a critical debate: should there be a targeted prostate cancer screening program for Black men, who face a staggering one in four lifetime risk of the disease, compared to one in eight for men overall?
Hemans, now successfully treated, is a vocal advocate for change. ‘If a screening program had been in place when I was 51, I could’ve been diagnosed earlier,’ he reflects. ‘Screening doesn’t just save lives—it saves them better and cheaper.’ His story isn’t unique. Prostate cancer has surpassed breast cancer as the most commonly diagnosed cancer in England, with over 55,000 new cases annually. Yet, there’s still no national screening program in place. And this is the part most people miss: Black men are not only at higher risk but also face a greater likelihood of late-stage diagnosis and higher mortality rates, even in affluent areas.
Keith Morgan, from Prostate Cancer UK, argues the case for targeted screening is ‘particularly strong.’ ‘Leaving screening to chance perpetuates deadly inequalities,’ he says. ‘It’s not just about where you live—it’s about who you are.’ Experts like Morgan are urging the UK National Screening Committee (NSC) to recommend an NHS program focused on high-risk groups, especially Black men. But not everyone agrees. Some researchers, like Naser Turabi from Cancer Research UK, caution that the evidence for targeted screening is still ‘very unclear.’ They worry about potential over-diagnosis, particularly since Black men naturally have higher PSA levels, which could skew results.
Here’s the kicker: even within the Black community, there’s significant genetic diversity, and lumping everyone into a single category could overlook crucial nuances. ‘Black is a social category, not a genetic one,’ Turabi points out. This complexity is further compounded by a lack of genomic data on Black men, making it harder to draw definitive conclusions. Rhian Gabe, a biostatistics professor leading the £42m Transform trial, acknowledges the gap: ‘We need more research that includes Black men, and that’s exactly what we’re aiming to do.’
So, where does this leave us? The NSC’s decision, expected soon, could be a game-changer—or not. If they reject targeted screening, advocates like Morgan vow to push the government for urgent action on awareness and updated guidelines. David James, from Prostate Cancer Research, is optimistic: ‘We’ve shown that targeted screening is cost-effective and won’t overwhelm the NHS.’ But the debate rages on. Is targeted screening the answer, or are we risking over-diagnosis and oversimplification? What do you think? Should we prioritize equity in screening, even if the science isn’t perfect? Let’s hear your thoughts in the comments—this conversation is far from over.
